Spasticity – Executive Insights – Adult Spasticity | Executive Insights | US/EU5/China
Spasticity is characterized by an increase in muscle tone and is highly prevalent among patients diagnosed with some neurological conditions (e.g., stroke, multiple sclerosis [MS], spinal cord injury [SCI], traumatic brain injury [TBI]). Wide arrays of therapies are available to treat adult spasticity, including oral anti-spasticity drugs, botulinum toxins, cannabinoids, and intrathecal interventions. However, oral drugs that are generically available (i.e., baclofen and tizanidine) are the most prescribed first-line treatments, followed by the more-efficacious invasive botulinum toxin A therapies (AbbVie’s Botox, Ipsen’s Dysport, Merz’s Xeomin) in later lines. Although current therapies are effective in decreasing muscle tone and improving the quality of life, they have multiple shortcomings (e.g., safety concerns). In addition, late-phase pipeline activity for the treatment of adult spasticity is sparse, with many emerging agents lacking a novel mechanism of action. Interviewed neurologists have highlighted areas of unmet need and expressed expectations from an emerging therapy in adult spasticity. Given the extent of disease burden on patients, neurologists are open to adopt treatment options that demonstrate benefits over the current therapies.
Questions Answered
- What is the prevalence rate of adult spasticity in neurological conditions such as stroke, MS, SCI, and TBI?
- What are the physician-perceived advantages and disadvantages of current treatments in adult spasticity, including the marketed botulinum toxins? What is the patient journey in adult spasticity?
- What are the key areas of unmet need and opportunity in the management of adult spasticity?
- What is the competitive landscape and the expected future influence of key emerging drugs for the treatment of adult spasticity?
- What are the key drivers and limiters of the adult spasticity market currently and in the future, along with the SWOT analysis?
Product Description: Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geographies: United States, EU5, China.
Primary research: 8 interviews with neurologists in February 2022.
Key companies covered: AbbVie, Ipsen Pharma, Merz Therapeutics, Amneal Pharmaceuticals, Jazz Pharmaceuticals, Revance Therapeutics, Bionorica, RVL Pharmaceuticals, Supernus Pharmaceuticals
Key drugs covered: Botox, Dysport, Xeomin, MyoBloc / NeuroBloc, tizanidine, baclofen, Sativex, Ontinua ER, daxibotulinumtoxinA (DAXI), Gablofen, Ozobax, Lioresal Intrathecal, biosimilar of onabotulinumtoxinA
Sanjivani Mishra, M.Sc. Biotech., Senior Healthcare Research & Data Analyst, CNS and Ophthalmology. Ms. Mishra’s focus is the CNS therapy market. Previously, she was a consultant at IQVIA. In this role, she worked on forecasting the pharmaceutical market in south Asian countries. She holds a master’s degree in biotechnology from Pune University in India.
Himanshu Jain, M.S.(Pharm.), Senior Manager, CNS and Ophthalmology. He has authored content for psychiatry and ophthalmology indications, including forecasting markets for schizophrenia, depression, and dry eye disease. He has about 15 years of experience working in market research and consulting firms. He earned his master’s degree in Pharmacology & Toxicology from the National Institute of Pharmaceutical Education and Research and holds an Executive Post-Graduate Diploma in International Business from the Indian Institute of Foreign Trade.